Table 2 Trajectory of clinical data between the two groups
Factor | SZC group (N = 14) | HD group (N = 7) | p value |
|---|---|---|---|
Data at the onset of acute hyperkalemia | |||
Urgent hospitalization (number, %) | 2 (14.3) | 7 (100.0) | < 0.001* |
Electrocardiogram (number, %) | 10 (71.4) | 7 (100.0) | 0.25 |
Complete atrioventricular block (number, %) | 1 (10.0) | 5 (71.4) | 0.035* |
Temporary pacemaker insertion (number, %) | 0 (0.0) | 2 (28.6) | 0.10 |
Serum creatinine (mg/dL) | 2.60 [1.96, 3.06] | 4.77 [3.06, 5.61] | 0.044* |
Serum potassium (mEq/L) | 6.8 [6.3, 7.0] | 8.0 [6.6, 8.3] | 0.13 |
Serum sodium chloride gap (mEq/L) | 31 [26, 33] | 34 [30, 35] | 0.29 |
Hyperkalemia treatment other than SZC or HD (number, %) | 2 (14.3) | 4 (57.1) | 0.12 |
Therapeutic duration (days) | 3 [2, 7] | 1 [1] | 0.0026* |
Post-treatment data | |||
Serum creatinine (mg/dL) | 2.40 [2.14, 3.59] | 2.84 [1.88, 3.55] | 0.94 |
Serum potassium (mEq/L) | 4.7 [4.4, 5.3] | 4.8 [4.4, 5.3] | 0.85 |
Serum sodium chloride gap (mEq/L) | 32 [31, 35] | 33 [33, 34] | 0.82 |
Data at 3-month follow-up | |||
SZC use (number, %) | 4 (30.8) | 0 (0.0) | 0.25 |
Other potassium adsorbent use (number, %) | 6 (46.2) | 3 (42.9) | 1.00 |
Use of RAS inhibitors (number, %) | 9 (64.2) | 3 (42.8) | 0.40 |
Use of mineralocorticoid receptor antagonist (number, %) | 4 (28.6) | 1 (14.3) | 0.62 |
Serum creatinine (mg/dL) | 2.22 [1.66, 3.27] | 1.21 [1.00, 3.39] | 0.27 |
Serum potassium (mEq/L) | 4.8 [4.6, 4.9] | 4.7 [4.5, 5.1] | 0.93 |
Serum sodium chloride gap (mEq/L) | 34 [32, 37] | 34 [33, 35] | 0.83 |